Viewing nowSitagliptin Tablets 50 mg (Sitagliptin Phosphate)
Sitagliptin Phosphate 62.04mg
Tablet · Prescription medication
Korea Prime Pharmaceutical Co., Ltd.

MFDS item code 201503228 · Approved 2015.05.27 · Insurance code 663607520
Improvement of glycemic control in type 2 diabetes mellitus
This medication serves to assist dietary and exercise therapy in improving blood sugar control in patients with type 2 diabetes. It can be administered as a monotherapy initially, and in patients with uncontrolled blood glucose who have not previously received diabetes treatment, it is used in combination with metformin. Additionally, when blood sugar control is insufficient with sulfonylurea, metformin, thiazolidinedione, or insulin monotherapy, it is treated in combination with this medication. A treatment regimen which adds this medication is also used when control remains difficult with combinations of sulfonylurea and metformin, thiazolidinedione and metformin, or insulin and metformin. This medication effectively improves blood sugar control across various treatment combinations.
Administer 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This medicine may be taken with or without food. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because dosage adjustment is required according to renal function, assessment of renal function is recommended before starting this medicine and periodically during treatment. 1. No dosage adjustment is necessary in patients with mild renal impairment (glomerular filtration rate [eGFR] ≥ 60mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is necessary in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 45mL/min/1.73 m2 and < 60mL/min/1.73 m2). 3. Administer 50 mg once daily in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 30mL/min/1.73 m2 and < 45mL/min/1.73 m2). 4. Administer 25 mg once daily in patients with severe renal impairment (glomerular filtration rate [eGFR] ≥ 15mL/min/1.73 m2 and < 30mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered regardless of the timing of dialysis.
This medication may cause allergic reactions; if rash, difficulty breathing, swelling, or other symptoms appear, usage should be stopped immediately and a doctor should be consulted. While taking this medication, inflammation of the pancreas, known as pancreatitis, may occur. If symptoms such as abdominal pain, vomiting, or nausea arise, inform healthcare professionals immediately. This medication should not be used in patients with type 1 diabetes or diabetic ketoacidosis, and it should be avoided in patients with allergies to this medication or its components. Patients with impaired kidney function may need to adjust the dosage of this medication, therefore, it should be taken according to a doctor's instructions. While taking this medication there may be side effects such as upper respiratory infections, nasopharyngitis, headache, diarrhea, nausea, and others; if symptoms worsen, consult a doctor. There is an increased risk of hypoglycemia when this medication is used in combination with other antidiabetic drugs, particularly insulin or sulfonylureas, so it is necessary to monitor blood sugar levels regularly and adjust the dosage as needed. This medication may cause severe joint pain or blistering skin conditions, so if there is severe joint pain or blisters or rashes appear on the skin, inform a doctor immediately. It is advisable for pregnant or breastfeeding women not to use this medication, and safety has not been established for children or adolescents under 18 years of age. Elderly patients may experience decreased kidney function, so renal function tests should be performed before use, and dosage adjusted according to a doctor's guidance. In case of overdose, general treatments such as gastrointestinal decontamination and ECG monitoring may be required, and some drug may be removed through hemodialysis. This medication has relatively few interactions with other drugs, but when used with digoxin, blood concentration should be monitored. If unusual symptoms develop during use, it is important to consult healthcare professionals immediately for appropriate measures.
Severe hypersensitivity reactions, anaphylaxis, angioedema, Stevens-Johnson syndrome, exfoliative skin diseases, acute pancreatitis, hypoglycemia, upper respiratory infections, nasopharyngitis, headache, diarrhea, abdominal pain, nausea, peripheral edema, constipation, vomiting, arthralgia accompanied by severe conditions and disabilities, bullous pemphigoid-like dermatitis, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis, elevated liver enzymes, acute renal failure, pneumonia, diabetic complications, metabolic acidosis, falls, cardiac arrest, dyspepsia, dizziness, elevated serum triglycerides, gastritis, weight loss, hypertension, hypernatremia, erectile dysfunction
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air from entering and is best kept at a temperature between 1°C and 30°C. Proper storage will help maintain the medication's efficacy.
A round film-coated tablet with a bright beige color and a biconvex shape.
30 tablets/box [10 tablets/PTP X 3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowSitagliptin Phosphate 62.04mg
Tablet · Prescription medication
Korea Prime Pharmaceutical Co., Ltd.

Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication
Jongkeundang Co., Ltd.

Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Jongkundang Co., Ltd.

Sitagliptin Phosphate Hydrate 32.13mg
Tablet · Prescription medication
Jong Kundang Co., Ltd.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Vivozon Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 32.125mg
Tablet · Prescription medication
Sinpoong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.